JP2020534274A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534274A5 JP2020534274A5 JP2020515077A JP2020515077A JP2020534274A5 JP 2020534274 A5 JP2020534274 A5 JP 2020534274A5 JP 2020515077 A JP2020515077 A JP 2020515077A JP 2020515077 A JP2020515077 A JP 2020515077A JP 2020534274 A5 JP2020534274 A5 JP 2020534274A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- pharmaceutical composition
- hydrogen
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- -1 cyano, formyl Chemical group 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 4
- 230000009529 traumatic brain injury Effects 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 2
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical group SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000017004 dementia pugilistica Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 206010048962 Brain oedema Diseases 0.000 claims 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000005018 aryl alkenyl group Chemical group 0.000 claims 1
- 125000005127 aryl alkoxy alkyl group Chemical group 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- 125000005015 aryl alkynyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000005963 oxadiazolidinyl group Chemical group 0.000 claims 1
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 150000003053 piperidines Chemical class 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 1
- 125000005304 thiadiazolidinyl group Chemical group 0.000 claims 1
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 1
- 150000003573 thiols Chemical group 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 0 BC(*)(*C)N(C(*)C1(C)*)C1=O Chemical compound BC(*)(*C)N(C(*)C1(C)*)C1=O 0.000 description 12
- KQUQJHZJTWYGAQ-UHFFFAOYSA-N C(C1CCNCC1)N1CCCCC1 Chemical compound C(C1CCNCC1)N1CCCCC1 KQUQJHZJTWYGAQ-UHFFFAOYSA-N 0.000 description 1
- XPDSXKIDJNKIQY-UHFFFAOYSA-N C(CC1)CCC1N1CCNCC1 Chemical compound C(CC1)CCC1N1CCNCC1 XPDSXKIDJNKIQY-UHFFFAOYSA-N 0.000 description 1
- QDVBKXJMLILLLB-UHFFFAOYSA-N C(CC1)CCN1C1CCNCC1 Chemical compound C(CC1)CCN1C1CCNCC1 QDVBKXJMLILLLB-UHFFFAOYSA-N 0.000 description 1
- FKYVHDSPGMMDFF-UHFFFAOYSA-N C(CN1CCCCC1)C1CCNCC1 Chemical compound C(CN1CCCCC1)C1CCNCC1 FKYVHDSPGMMDFF-UHFFFAOYSA-N 0.000 description 1
- LKUAPSRIYZLAAO-UHFFFAOYSA-N C(CN1CCNCC1)c1ccccc1 Chemical compound C(CN1CCNCC1)c1ccccc1 LKUAPSRIYZLAAO-UHFFFAOYSA-N 0.000 description 1
- IQXXEPZFOOTTBA-UHFFFAOYSA-N C(c1ccccc1)N1CCNCC1 Chemical compound C(c1ccccc1)N1CCNCC1 IQXXEPZFOOTTBA-UHFFFAOYSA-N 0.000 description 1
- CDGJGXXSONVEFL-ANLCFORVSA-N C=C[C@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)N([C@H](COCc2ccccc2)C(C2CCN(CN3CCCCC3)CC2)=O)C1=O Chemical compound C=C[C@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)N([C@H](COCc2ccccc2)C(C2CCN(CN3CCCCC3)CC2)=O)C1=O CDGJGXXSONVEFL-ANLCFORVSA-N 0.000 description 1
- IFDLFCDWOFLKEB-UHFFFAOYSA-N CCC(C)Cc1ccccc1 Chemical compound CCC(C)Cc1ccccc1 IFDLFCDWOFLKEB-UHFFFAOYSA-N 0.000 description 1
- OCKPCBLVNKHBMX-UHFFFAOYSA-N CCCCc1ccccc1 Chemical compound CCCCc1ccccc1 OCKPCBLVNKHBMX-UHFFFAOYSA-N 0.000 description 1
- CTXVGAPEUMTYNI-BEMMEUOBSA-N CN(Cc1cc(C(F)(F)F)ccc1)C([C@@H](CC(N(CC1)CCC1N1CCCCC1)=O)N([C@@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)C=C)C1=O)=O Chemical compound CN(Cc1cc(C(F)(F)F)ccc1)C([C@@H](CC(N(CC1)CCC1N1CCCCC1)=O)N([C@@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)C=C)C1=O)=O CTXVGAPEUMTYNI-BEMMEUOBSA-N 0.000 description 1
- FJUKOXWSIGULLE-VZFXNNIISA-N C[C@H](c1ccccc1)NC(C(CC(N(CC1)CCC1N1CCCCC1)=O)N([C@@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)/C=C/c2ccccc2)C1=O)=O Chemical compound C[C@H](c1ccccc1)NC(C(CC(N(CC1)CCC1N1CCCCC1)=O)N([C@@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)/C=C/c2ccccc2)C1=O)=O FJUKOXWSIGULLE-VZFXNNIISA-N 0.000 description 1
- VBXHSGJTMUBAJO-AFAPVMNMSA-N C[C@H](c1ccccc1)NC([C@@H](CC(N(CC1)CCC1N1CCCCC1)=O)N([C@@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)/C=C/c2cccc(I)c2)C1=O)=O Chemical compound C[C@H](c1ccccc1)NC([C@@H](CC(N(CC1)CCC1N1CCCCC1)=O)N([C@@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)/C=C/c2cccc(I)c2)C1=O)=O VBXHSGJTMUBAJO-AFAPVMNMSA-N 0.000 description 1
- KKIMDKMETPPURN-UHFFFAOYSA-N FC(c1cccc(N2CCNCC2)c1)(F)F Chemical compound FC(c1cccc(N2CCNCC2)c1)(F)F KKIMDKMETPPURN-UHFFFAOYSA-N 0.000 description 1
- CJNRGSHEMCMUOE-UHFFFAOYSA-N NCCN1CCCCC1 Chemical compound NCCN1CCCCC1 CJNRGSHEMCMUOE-UHFFFAOYSA-N 0.000 description 1
- MSLWUURVHWDPBY-UQENTHRZSA-N O=C([C@@H](COCc1ccccc1)N([C@@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)/C=C/c2ccccc2)C1=O)C1CCN(CCN2CCCCC2)CC1 Chemical compound O=C([C@@H](COCc1ccccc1)N([C@@H]([C@@H]1N([C@H](CO2)c3ccccc3)C2=O)/C=C/c2ccccc2)C1=O)C1CCN(CCN2CCCCC2)CC1 MSLWUURVHWDPBY-UQENTHRZSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023161532A JP7699634B2 (ja) | 2017-09-15 | 2023-09-25 | 脳損傷を治療するための組成物及び方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762559113P | 2017-09-15 | 2017-09-15 | |
| US62/559,113 | 2017-09-15 | ||
| US201762584343P | 2017-11-10 | 2017-11-10 | |
| US62/584,343 | 2017-11-10 | ||
| US201862658758P | 2018-04-17 | 2018-04-17 | |
| US62/658,758 | 2018-04-17 | ||
| PCT/US2018/051331 WO2019055913A1 (en) | 2017-09-15 | 2018-09-17 | COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023161532A Division JP7699634B2 (ja) | 2017-09-15 | 2023-09-25 | 脳損傷を治療するための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020534274A JP2020534274A (ja) | 2020-11-26 |
| JP2020534274A5 true JP2020534274A5 (enExample) | 2021-10-28 |
Family
ID=65723435
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515077A Pending JP2020534274A (ja) | 2017-09-15 | 2018-09-17 | 脳損傷を治療するための組成物及び方法 |
| JP2023161532A Active JP7699634B2 (ja) | 2017-09-15 | 2023-09-25 | 脳損傷を治療するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023161532A Active JP7699634B2 (ja) | 2017-09-15 | 2023-09-25 | 脳損傷を治療するための組成物及び方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11628160B2 (enExample) |
| EP (1) | EP3681871A4 (enExample) |
| JP (2) | JP2020534274A (enExample) |
| KR (1) | KR102790657B1 (enExample) |
| CN (1) | CN111295373B (enExample) |
| AU (1) | AU2018333051B2 (enExample) |
| BR (1) | BR112020005107A2 (enExample) |
| CA (1) | CA3075759A1 (enExample) |
| IL (1) | IL273228B2 (enExample) |
| MX (1) | MX2020002762A (enExample) |
| MY (1) | MY208313A (enExample) |
| TW (1) | TW201919625A (enExample) |
| WO (1) | WO2019055913A1 (enExample) |
| ZA (1) | ZA202001880B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2662350T3 (es) | 2010-07-01 | 2018-04-06 | Azevan Pharmaceuticals, Inc. | Procedimientos para el tratamiento del trastorno por estrés postraumático |
| US9802925B2 (en) | 2014-03-28 | 2017-10-31 | Azevan Pharmaceuticals, Inc. | Compositions and methods for treating neurodegenerative diseases |
| CA3018375A1 (en) * | 2016-03-30 | 2017-10-05 | Carin Sjolund | Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages |
| MX2020002762A (es) | 2017-09-15 | 2020-09-17 | Azevan Pharmaceuticals Inc | Composiciones y métodos para tratar una lesión cerebral. |
| US11583538B2 (en) | 2019-04-08 | 2023-02-21 | Venenum Biodesign, LLC | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors |
| WO2022075974A1 (en) * | 2020-10-06 | 2022-04-14 | Venenum Biodesign, LLC | Cyclic trex1 inhibitors |
| CN115350186A (zh) * | 2022-08-31 | 2022-11-18 | 中国人民解放军军事科学院军事医学研究院 | Sxr246在制备治疗创伤性脑损伤及预后不良药物中的应用 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
| US4314081A (en) | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| NL7503310A (nl) | 1975-03-20 | 1976-09-22 | Philips Nv | Verbindingen met antidepressieve werking. |
| US4576753A (en) | 1975-10-06 | 1986-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Azetidinone compounds and processes for preparation thereof |
| GB1526331A (en) | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| US4341698A (en) | 1979-06-21 | 1982-07-27 | Richardson-Merrell Inc. | Enkaphalin derivatives |
| US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| JPS56125361A (en) | 1980-03-07 | 1981-10-01 | Sagami Chem Res Center | Azetidinone compound |
| JPS6033439B2 (ja) | 1980-03-07 | 1985-08-02 | 財団法人相模中央化学研究所 | ジペプチドの製造方法 |
| FR2508035A1 (fr) | 1981-06-23 | 1982-12-24 | Fabre Sa Pierre | Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central |
| US4761501A (en) | 1983-10-26 | 1988-08-02 | American Home Products Corporation | Substituted phenylacetamides |
| US4751299A (en) | 1983-11-18 | 1988-06-14 | Takeda Chemical Industries, Ltd. | Optically active β-lactams and method of their production |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4734498A (en) | 1986-07-10 | 1988-03-29 | Eli Lilly And Company | 3β-succinimidoazetidinones as chiral intermediates |
| US4772694A (en) | 1986-07-24 | 1988-09-20 | Eli Lilly And Company | Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates |
| US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| CA2093125C (en) | 1990-10-02 | 2003-12-16 | Warner-Lambert Company | Angiotensin ii antagonists |
| GB9204001D0 (en) | 1992-02-25 | 1992-04-08 | Jacobs Suchard Ag | Process for producing reduced fat nuts |
| US5246943A (en) | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| US5612336A (en) | 1992-07-13 | 1997-03-18 | Merck, Sharp & Dohme Ltd. | Heterocyclic amide derivatives as tachykinin antagonists |
| DK0655055T3 (da) | 1992-08-13 | 2001-01-02 | Warner Lambert Co | Tachykininantagonister |
| FR2696178B1 (fr) | 1992-09-30 | 1994-12-30 | Sanofi Elf | Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant. |
| EP0696280B1 (en) | 1993-05-06 | 1997-09-24 | Merrell Pharmaceuticals Inc. | Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists |
| US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5759865A (en) | 1995-05-03 | 1998-06-02 | Eli Lilly And Company | Combinatorial process for synthesizing azetidinone analogs |
| GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| ES2248840T3 (es) | 1996-02-23 | 2006-03-16 | Eli Lilly And Company | Antagonistas de vasopresina v1a no peptidilicos. |
| IL130300A0 (en) | 1996-12-13 | 2000-06-01 | Lilly Co Eli | Inhibitors of the enzymatic activity of PSA |
| WO1998043976A1 (en) | 1997-03-31 | 1998-10-08 | Wakamoto Pharmaceutical Co., Ltd. | Biphenyl derivatives and medicinal compositions |
| DK1000062T3 (da) | 1997-07-30 | 2004-11-22 | Wyeth Corp | Tricykliske vasopressinagonister |
| US6403632B1 (en) | 2000-03-01 | 2002-06-11 | Bristol Myers Squibb Pharma Co | Lactam metalloprotease inhibitors |
| AU749505B2 (en) | 1997-10-27 | 2002-06-27 | Dr. Reddy's Laboratories Limited | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
| BR0013366A (pt) | 1999-08-16 | 2002-07-23 | Revaax Pharmaceuticals Llc | Métodos para tratar um distúrbio comportamental, um paciente humano, doença de próstata, distúrbios de ansiedade e cognitivos em um paciente humano afligido com uma condição ou disposto ao desenvolvimento de uma condição distinguida pelo menos em parte pela concentração de glutamato extracelular anormal no cérebro ou em outro tecido nervoso, distúrbio comportamental nas espécies humana, canina, felina e equina e um paciente afligido com ou disposto a desenvolver uma doença compreendendo concentrações de glutamato anormalmente elevadas em tecido neuronal ou nìveis de naaladase elevados em tecido prostático e com esclerose múltipla e para realçar a função cognitiva, formulação farmacêutica e usos de um inibidor da atividade de peptidase de uma dipeptidase ácida ligada em alfa n-acetilada e de um composto de beta-lactama |
| GB0019006D0 (en) | 2000-08-04 | 2000-09-20 | Astrazeneca Ab | Novel compounds |
| EP1434763B1 (en) | 2001-10-12 | 2018-01-17 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl vasopressin v1a antagonists |
| US7179907B2 (en) | 2001-12-18 | 2007-02-20 | Bruce Eaton | Antibiotic compounds |
| US7135479B2 (en) | 2002-09-12 | 2006-11-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans |
| GB0224919D0 (en) | 2002-10-25 | 2002-12-04 | Pfizer Ltd | Triazole compounds useful in therapy |
| US7132426B2 (en) | 2003-07-14 | 2006-11-07 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| WO2005035492A1 (en) | 2003-10-03 | 2005-04-21 | Serenix Pharmaceuticals, Llc. | 3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS |
| US7745630B2 (en) | 2003-12-22 | 2010-06-29 | Justin Stephen Bryans | Triazolyl piperidine arginine vasopressin receptor modulators |
| EP1632494A1 (en) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
| EP1669776A1 (de) | 2004-12-11 | 2006-06-14 | Leica Geosystems AG | Handhaltbares Vermessungsgerät und Vermessungsverfahren für ein solches Vermessungsgerät |
| FR2881744B1 (fr) | 2005-02-09 | 2007-04-27 | Sanofi Aventis Sa | Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique |
| AU2006227199A1 (en) | 2005-03-22 | 2006-09-28 | Azevan Pharmaceuticals, Inc. | Beta-lactamylalkanoic acids for treating premenstrual disorders |
| WO2006123242A1 (en) | 2005-05-18 | 2006-11-23 | Pfizer Limited | 1, 2, 4 -triazole derivatives as vasopressin antagonists |
| KR101523776B1 (ko) | 2005-07-19 | 2015-05-28 | 아제반 파마슈티칼스, 인코퍼레이티드 | 베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신길항물질 |
| WO2007109615A2 (en) | 2006-03-21 | 2007-09-27 | Azevan Pharmaceuticals, Inc. | β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS |
| WO2008034032A2 (en) | 2006-09-14 | 2008-03-20 | Azevan Pharmaceuticals, Inc. | Beta-lactam cannabinoid receptor modulators |
| JP2010504352A (ja) | 2006-09-22 | 2010-02-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | バソプレッシン拮抗薬としてのスピロベンズアゼピン類 |
| ATE532786T1 (de) * | 2006-09-22 | 2011-11-15 | Janssen Pharmaceutica Nv | Spirobenzazepine als vasopressinantagonisten |
| WO2008118718A2 (en) | 2007-03-23 | 2008-10-02 | Array Biopharma Inc. | 2-aminopyridine analogs as glucokinase activators |
| FR2927625B1 (fr) | 2008-02-19 | 2010-03-12 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique |
| FR2930249B1 (fr) | 2008-04-21 | 2010-05-14 | Sanofi Aventis | Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique. |
| ES2662350T3 (es) * | 2010-07-01 | 2018-04-06 | Azevan Pharmaceuticals, Inc. | Procedimientos para el tratamiento del trastorno por estrés postraumático |
| CN102156420B (zh) | 2010-12-23 | 2012-11-07 | 天津职业技术师范大学 | 加快从计算机下载数据到单片机目标存储器的装置 |
| EP2956441A4 (en) * | 2013-02-18 | 2016-11-02 | Scripps Research Inst | MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL |
| US9802925B2 (en) | 2014-03-28 | 2017-10-31 | Azevan Pharmaceuticals, Inc. | Compositions and methods for treating neurodegenerative diseases |
| MX2020002762A (es) * | 2017-09-15 | 2020-09-17 | Azevan Pharmaceuticals Inc | Composiciones y métodos para tratar una lesión cerebral. |
-
2018
- 2018-09-17 MX MX2020002762A patent/MX2020002762A/es unknown
- 2018-09-17 BR BR112020005107-1A patent/BR112020005107A2/pt unknown
- 2018-09-17 EP EP18855876.1A patent/EP3681871A4/en active Pending
- 2018-09-17 US US16/646,744 patent/US11628160B2/en active Active
- 2018-09-17 AU AU2018333051A patent/AU2018333051B2/en active Active
- 2018-09-17 KR KR1020207010875A patent/KR102790657B1/ko active Active
- 2018-09-17 TW TW107132685A patent/TW201919625A/zh unknown
- 2018-09-17 JP JP2020515077A patent/JP2020534274A/ja active Pending
- 2018-09-17 IL IL273228A patent/IL273228B2/en unknown
- 2018-09-17 MY MYPI2020001313A patent/MY208313A/en unknown
- 2018-09-17 WO PCT/US2018/051331 patent/WO2019055913A1/en not_active Ceased
- 2018-09-17 CA CA3075759A patent/CA3075759A1/en active Pending
- 2018-09-17 CN CN201880070936.8A patent/CN111295373B/zh active Active
-
2020
- 2020-03-24 ZA ZA2020/01880A patent/ZA202001880B/en unknown
-
2023
- 2023-04-17 US US18/135,225 patent/US20240115553A1/en not_active Abandoned
- 2023-09-25 JP JP2023161532A patent/JP7699634B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534274A5 (enExample) | ||
| JP2006524222A5 (enExample) | ||
| CY1109493T1 (el) | Παραγωγα οξαζολιου ως παραγοντες η3 υποδοχεα ισταμινης, παρασκευη και θεραπευτικες χρησεις | |
| SA518391518B1 (ar) | مشتقات n-] 2-(1- بنزيل ببريدين-4-يل) إيثيل[ -4-(بيرازين-2-يل)-ببرازين-1- كربوكساميد ومركبات متصلة بها كمضادات مستقبلة المسكارين 4 (m4) لمعالجة أمراض عصبية | |
| RU2010138577A (ru) | ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3 | |
| TNSN07164A1 (en) | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists | |
| JP2004520324A5 (enExample) | ||
| CO5550451A2 (es) | Derivados de 3-(sulfonamidoetil)-indol para uso como mimeti- cos de glucocorticoides en el tratamiento de enfermedades inflamatorias, alergicas y proliferativas | |
| JP2011512412A5 (enExample) | ||
| HRP20180199T1 (hr) | Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1) | |
| JP2015522650A5 (enExample) | ||
| NO20070213L (no) | Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser | |
| RU2010137115A (ru) | Производные 5,6-бисарил-2-пиридинкарбоксамидов, способ их получения и их применение в терапии в качестве антагонистов рецепторов | |
| TW200633698A (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
| RU2015116816A (ru) | Производное имидазола | |
| RU2016138349A (ru) | Композиции и способы лечения нейродегенеративных заболеваний | |
| JP2010536821A5 (enExample) | ||
| JP2005506982A5 (enExample) | ||
| RU2014144951A (ru) | Новое 1-замещенное производное индазола | |
| JP2009502788A5 (enExample) | ||
| CY1111744T1 (el) | Τροποποιητες της δραστηριοτητας toy υποδοχεα χημειοκινων, κρυσταλλικες μορφες και διεργασια | |
| EA201001645A1 (ru) | Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора | |
| ATE388939T1 (de) | N-((piperazinyl)hetaryl)arylsulfonamid-derivate mit affinität zum dopamin-d3-rezeptor | |
| RU2010126842A (ru) | Производные пиперазина и их применение в качестве модуляторов рецептора лептина | |
| JP2017516824A5 (enExample) |